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The Joint United Nations Programme on HIV/AIDS (UNAIDS) 
90-90-90 strategy ambitiously aspires to have 90% of people living with 
HIV (PLWH) know their status, 90% to receive sustained antiretroviral 
treatment (ART) and 90% to achieve viral load (VL) suppression 
by 2020.[1] Many studies in different settings have assessed progress 
compared with these targets, with significant heterogeneity in data 
sources, outcome definitions, methods and results.[2]
The Khayelitsha cohort in Cape Town, South Africa (SA) is one 
of the oldest and largest HIV cohorts in the country. Free public sec-
tor ART was initially rolled out in SA in 2001, in partnership with 
Médecins Sans Frontières.[3] VL testing is the gold standard in HIV 
treatment monitoring.[4,5] Unusually for a low-resource setting, VL 
monitoring has been widely used in Khayelitsha since programme 
inception in 2001. With ~22 000 patients receiving ART and in care at 
provincial facilities in 2016, Khayelitsha reported almost 89% suppres sion 
in quarterly reports; however, there was only 56% comple tion of routine 
VL tests indicated by national guidelines (R Holtman, Western Cape 
Department of Health – personal commu nication, 2017). This low 
reported completion does not necessarily imply low actual comple-
tion, as it may be the result of incompleteness in routine data 
capturing.
For this study, the concept of a VL ‘cascade’ was introduced to 
represent the steps required for an ‘expected’ VL to be reported as 
complete in routine data and thus contribute to reported VL sup-
pression in routine quarterly reports (Fig. 1). As a first step, a blood 
sample was taken in patients in whom a routine VL was expected 
(step 1). This blood sample must then be processed by the laboratory 
(‘done’) (step 2), the test result printed, couriered to the facility, sorted 
and distributed to the appropriate registry and ‘filed’ by a clerk in 
the patient folder (step 3), the result ‘noted’ by a clinician in the visit 
summary paper stationery at the next clinical assessment (step 4) and 
electronically ‘captured’ by a clerk onto the primary healthcare infor-
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Background. The Joint United Nations Programme on HIV/AIDS (UNAIDS) third 90-90-90 target requires 90% of patients on antiretroviral 
treatment (ART) to be virally suppressed (<1 000 copies/mL). In Khayelitsha, Cape Town, South Africa viral load (VL) suppression of 
<400 copies/mL was reported as 89% in 2016, but only 56% of patients had a result recorded in routine data. We conceived a VL ‘cascade’ to 
represent the steps required for an expected VL to be reported as complete in routine data and thus contribute to reported VL suppression: 
among those for whom a VL is ‘expected’, a sample must be collected and tested (‘done’), a result must be ‘filed’ in the patient folder, ‘noted’ 
by a clinician and electronically ‘captured’. The low reported completion suggested gaps along the VL cascade and cast doubt on the validity 
of reported suppression.
Objectives. To assess the validity of routinely reported VL suppression and identify barriers to VL completion.
Methods. A retrospective cohort study between 1 July 2015 and 30 June 2016, which included all Khayelitsha patients receiving ART, with 
a routine VL expected, was conducted. We obtained data routinely captured on site and VL data from the laboratory system. A sample 
of 1 035 patient folders was reviewed. VL suppression was calculated using laboratory data, including all tests done, and compared with 
reported suppression based on on-site captured electronic data. Successful progression through each step on the VL cascade was estimated. 
We used logistic regression to identify factors associated with laboratory data and reported VL testing.
Results. Of 22  991 patients for whom a routine VL test was due, 84% were done, 79% filed, 76% noted and 55% captured. Using all 
laboratory data, VL suppression was estimated as 82%, 87%, 89% and 91% at the 50, 200, 400 and 1 000 copies/mL thresholds, respectively, 
but reported suppression using captured results was 80%, 86%, 88% and 89% at those thresholds. Routine VL testing is more likely to be 
done in children <15 years old (adjusted odds ratio (aOR) 1.89, 95% confidence interval (CI) 1.45 - 2.48) and pregnant women (aOR 1.90, 
95% CI 1.28 - 2.81) than in men, adjusted for facility.
Conclusions. Despite a low reported completion, VL testing completion was high. Reported suppression using captured data was similar to 
suppression calculated using all laboratory data, which provided an accurate measure of progress towards the 90-90-90 target. More work 
is needed to reach the 16% of patients missed by routine testing.
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mation system (PHCIS) (step 5). Finally, 
as routine quarterly ART data report on 
facility-based ART-naive cohorts, VL results 
for patients who initiated outside the facility 
at which they were being cared for were not 
included in reports (step 6).
The low reported completion for Khaye-
litsha in 2016 therefore raised two important 
questions: was the high reported suppres-
sion proportion a valid measure of progress 
towards the third 90, and what were the bar-
riers to testing and recording of VL results 
in the context of widely available laboratory 
testing? This study aimed to answer these 
questions by describing a VL cascade from 
expected to reported, and estimating success 
and failure at each step on the cascade.
Methods
Setting
The Khayelitsha cohort has been described 
in detail elsewhere.[6] Briefly, Khayelitsha is 
the largest township in Cape Town, with a 
high burden of HIV. The provincial govern-
ment initiated the provision of free ART 
services at primary healthcare facilities in 
2001.[3] Eligibility criteria have evolved in 
response to World Health Organization (WHO) 
recommendations, with universal test and 
treat adopted nationally in September 2016.[7]
Study design
A retrospective cohort was constructed, 
including all patients on ART and in 
care at provincial healthcare facilities in 
Khayelitsha, with a routine VL expected 
during 1 July 2015 - 30 June 2016.
Population
In the ART programme in SA, routine 
quarterly reports follow naive cohorts while 
in care at their initiating facility. Patients 
who die, transfer out or are lost to follow-up 
(defined as 90 days without medication in 
hand) exit the cohort. Even if they return to 
care elsewhere, they are no longer included 
in the reported suppression proportion. 
By contrast, the intended denominator for 
the ‘third 90’ includes all patients receiving 
ART, regardless of where they access care. 
This study included all patients receiving 
ART in Khayelitsha during the study period, 
irrespective of where they initiated ART, but 
distinguished between patients who are part 
of the reporting cohort (the naive cohort at 
the reporting facility) and those who are not. 
Outcomes
Suppression
National guidelines define VL suppression 
as <400 copies/mL. While the UNAIDS 
90-90-90 document does not explicitly 
define a threshold, it is generally taken to be 
˂1 000 copies/mL, although various thresholds 
have been used in different settings.[8] To 
assess the effect of using different thresh-
olds and facilitate comparability across 
studies, we reported at multiple thresholds.
Completion
Provincial guidelines recommend routine 
VL testing for all ART patients at 4 months, 
again at 12 months and annually thereafter.[9] 
More frequent testing is recommended after 
an unsuppressed VL or regimen switch, in 
HIV-exposed infants, HIV-positive child -
ren <5 years of age and pregnant and breast-
feeding women. To calculate routine VL 
completion, we calculated patient-specific 
window periods around each expected VL 
due date based on the patient’s ART ini-
tiation date, using the same algorithms as 
those in routine reports (Fig. 2). The algo-
rithm depicted in Fig. 2 is the same for all 
patients, despite the different clinical guide-
lines alluded to above. According to this 
algorithm, where >1 VL was taken within an 
allocation window, the VL on the date closest 
to the due date was used and others were 
excluded from reports.
Data collection
We used 3 data sources to assess completion 
at each step of the cascade: PHCIS, the 
Provincial Health Data Centre (PHDC) and 
the physical patient folder containing all 
paper records at the facility (Fig. 1). To 
assess completion at steps 0, 2 and 5 on 
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Fig. 1. Viral load cascade – from expected to reported. (ART = antiretroviral treatment; PHDC = 
Provincial Health Data Centre; PHCIS = primary healthcare information system.)
Routine VL 'expected' at 24 months
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Fig. 2. Viral load allocation, using a 24-month due date as an example. (VL = viral load; ART = antiretroviral treatment.) 
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the cascade, data were requested from PHCIS and PHDC. PHCIS 
contains routine data digitised by clerks on site. PHDC contains all 
data from the National Health Laboratory Service (NHLS), which 
performs all VL testing for patients in care at provincial facilities in 
Khayelitsha. All VL testing during the study period was performed 
by the NHLS using an Ampliprep/COBAS TaqMan HIV-1 Test v2 
(Roche, Switzerland). Step 1 could not be directly assessed, e.g. if a 
test was not registered by the laboratory system owing to incorrect 
or illegible request forms, it would not be counted as done at step 2, 
despite a blood sample having been taken within the window period 
and sent to the laboratory. Completion at steps 3 and 4 was assessed 
by physical folder review, for which folders were drawn on site at 
facilities and some data captured directly to a stand-alone encrypted 
electronic database. Routine patient data in all sources (physical 
folder, PHCIS, NHLS and PHDC) were captured and linked with the 
unique patient identifier used across the public health platform in 
Western Cape Province.[10]
Data analysis
The VL cascade is simplified insofar as it reports the furthest step 
a VL reached on the cascade and assumes that the VL successfully 
reached all previous steps. Only VLs done (step 2) but not captured 
(step 5) were sampled for physical folder review. The folder review 
then generated proportions of the sample, which were filed (step 3) 
and noted (step 4). These proportions (of the sample) could then 
be added to the proportion captured (of the total) to generate the 
proportions filed and noted on the cascade.
Statistical analyses were performed using Stata 14 (StataCorp., 
USA). The sample of folders selected for review was prepared using 
the simple random sample function, clustered on healthcare facility.
A logistic regression model was built to investigate the effect of 
facility, age category and pregnancy status on VL testing completion 
(done) and inclusion in routine reports (reported). Healthcare facility 
was included to account for different operational practices at different 
facilities. Age category and pregnancy status were included because 
different models of care are provided for children and pregnant 
women and different clinical guidelines are followed. Adjusted odds 
ratios (aORs) with 95% confidence intervals (CIs) were estimated 
using this model.
Ethical approval
The research was approved by the Faculty of Health Sciences Human 
Research Ethics Committee at the University of Cape Town (ref. no. 
HREC: 270/2017).
Results
There were 22 991 patients receiving ART and in care at provincial 
healthcare facilities in Khayelitsha between 1 July 2015 and 30 June 2016 
with a VL expected, of whom 18  450 (84%) had a VL performed 
within their window period. Of these, 11 100 (60%) were included 
in the reported suppression proportion in routine data: 1 790 (10%) 
patients were excluded because they were not part of the naive cohort 
at the reporting facility, and 5 560 (30%) were excluded because they 
were not captured (step 5). Of those not captured, 1 035 physical 
folders were reviewed, and completion at steps on the cascade was 
estimated to be 84% done (VL sample taken and tested), 79% filed, 
76% noted by a clinician, and 55% captured electronically.
Actual completion (done) and reported completion (reported) 
varied by facility, age category and pregnancy status (Table 1). 
Expected VLs were less than half as likely to be done at facility C than 
at facility A (aOR 0.46, 95% CI 0.42 - 0.51). Expected VLs at facility C were 
also less likely to be included in the reported suppression proportion 
(aOR 0.74, 95% CI 0.69 - 0.78). Children ˂15 years of age were more 
likely than men to have a routine VL done (aOR 1.89, 95% CI 1.45 - 
2.48). Despite pregnant women being almost twice as likely as men to 
have a VL test done within the routine window period, their results 
were 0.60 times as likely to be included in reported suppression 
proportions (aOR 1.90, 95% CI 1.28 - 2.81 and aOR 0.60, 95% CI 0.47 
- 0.77, respectively). The inclusion of duration on ART in the model 
made no meaningful difference to the effect estimates in the model 
(Supplementary Table 1).*
Suppressed VLs of <400 copies/mL were slightly less likely to be 
included in reported suppression proportions (aOR 0.70, 95% CI 0.63 
- 0.77). Actual VL suppression among all the VLs done, calculated 
using laboratory data, was 82%, 87%, 89% and 91% at the 50, 200, 400 
and 1 000 copies/mL thresholds, respectively, but reported suppression 
would have been 80%, 86%, 88% and 89% at those same thresholds. 
Discussion
The reported VL suppression proportion of <400 copies/mL from 
routine data (89%) differed by only 1% when all VL results from the 
laboratory were included, despite only 60% contributing to reported 
suppression. This confirms that Khayelitsha is very close to achieving 
the third 90 among those with available results. However, taking 
into consideration the 16% of patients not tested, the proportion of 
patients with confirmed suppression of <400 copies/mL declined 
to 75% of those receiving ART and in care. This is concerning, as 
it implies that even as we successfully increase ART coverage, the 
proportion of patients on ART who may be at risk of transmitting 
HIV remains between 10% and 25%.
Reported completion proportions were low, mostly owing to failure 
to test patients (16%) and failure to capture VL results electronically 
(21%). A trial is currently being performed of the inclusion of 
electronically imported test results from laboratory systems in 
routine quarterly reports in the Western Cape and would obviate the 
need for manual capturing of the results into PHCIS. However, the 
advantage of manual capturing from the folder was that it allowed for 
indirect monitoring of other steps in the VL cascade, as the presence 
of a VL result in routine data suggested successful progress through 
previous steps. Specifically, it implied that the result was available to 
the clinician at the next clinical assessment, as the clinician had to 
note it in the stationery for a clerk to capture electronically. Importing 
results will improve the completeness of data in routine reports, but it 
will no longer be possible to make inferences regarding intermediate 
steps on the VL cascade from routine data. Reassuringly, there was 
relatively little loss on the cascade between VL being done (step 2), 
filed (step 3) and noted (step 4), implying that results from VL tests 
that were done were usually available to clinicians at the next clinical 
assessment.
Our results suggest that if electronic import of test results from 
laboratory systems is successfully implemented, the reported VL 
completion proportion will increase substantially, but there will be little 
effect on the reported suppression proportion. Importantly, this study 
only assessed whether clinicians noted the VL results in the folder; 
it did not attempt to assess the effective use of VL results for clinical 
decision-making. Further research in this important area is required.
The variation in actual completion between facilities based on 
labora tory data suggests facility-specific challenges that require fur-
ther investigation. The variation by pregnancy status and age category 
was expected, as clinical guidelines recommend more frequent test-
ing for pregnant women and children.
The under-representation of pregnant women in the reported 
suppression proportion may be due to increased mobility during 
pregnancy because of movement between integrated maternal ART 
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clinics and routine ART clinics.[11] As discussed above, routine 
reports include only facility-specific naive ART cohorts. However, 
this deserves further investigation, as pregnant and breastfeeding 
women are vulnerable groups and viral suppression is critical to 
prevent vertical transmission.[12] Since the conclusion of this study, a 
separate routine quarterly report specifically for pregnant women was 
mandated by the national government.
Overall, actual completion was relatively high, but more must 
be done to close the gaps and reach patients who are not being 
tested, especially men and non-pregnant women. Suppressed and 
unsuppressed VL results inform patient management and clinical 
care. A suppressed VL may be used along with other indications to 
identify patients for recruitment to differentiated models of care, 
while an unsuppressed VL alerts a clinician to possible adherence 
challenges or drug resistance. We noted above that suppressed 
VL results were slightly less likely to successfully complete the VL 
cascade than unsuppressed VL results. This might suggest missed 
opportunities to recruit stable patients to differentiated models of 
care, thereby unburdening the health facilities. It also suggests that 
routine data may minimally underestimate the success of the ART 
programme.
Study limitations and strengths
This study has limitations. Firstly, the small proportion of requested 
VLs that were not successfully processed by the laboratory could 
not be estimated. Secondly, in routine quarterly ART reports, and in 
the third 90 as defined by UNAIDS, the suppression proportion was 
calculated at a point in time using a single VL. By contrast, sustained 
suppression over time is required to reap the full benefits of ART 
and mitigate the risk of transmission. Thirdly, the results of this 
study may not be generalisable regarding other settings. Three large 
provincial facilities were included and, while the main findings are 
likely to apply to similar facilities in metropolitan areas of SA, some 
of the results may not be generalisable with regard to settings outside 
Khayelitsha.
Strengths of this study include the assessment of routine data on 
>20 000 patients from multiple facilities, including adults, pregnant 
women and children. This was made possible by close collaboration 
with the Provincial Department of Health, and the availability of 
harmonised data from different data sources in the health system 
provided by PHDC.
Conclusion
Despite low reported VL completion, actual VL testing completion 
was high. The study confirmed the high levels of suppression that 
are routinely reported. More work is needed to reach the 16% of 
patients missed by routine testing. Most VL results were accessed and 
noted by clinicians, and further research is necessary to assess how 
effectively these results are used in clinical decision-making.
*Supplementary data. Supplementary Table 1 is available from the corres-
ponding author on request.
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n (%) aOR (95% CI) n (%) aOR (95% CI)
Facility A 7 129 (32) 6 313 (34) 1.00 3 815 (34) 1.00
Facility B 5 916 (27) 5 130 (28) 0.84 (0.76 - 0.94) 3 181 (29) 1.01 (0.94 - 1.08)
Facility C 8 946 (41) 7 007 (38) 0.46 (0.42 - 0.51) 4 104 (37) 0.74 (0.69 - 0.78)
Men 6 097 (28) 5 012 (27) 1.00 3 138 (28) 1.00
Non-pregnant women 15 011 (68) 12 649 (69) 1.17 (1.08 - 1.27) 7 546 (68) 0.96 (0.90 - 1.01)
Pregnant women 275 (1) 246 (1) 1.90 (1.28 - 2.81) 107 (1) 0.60 (0.47 - 0.77)
Children <15 years 608 (3) 543 (3) 1.89 (1.45 - 2.48) 309 (3) 0.99 (0.84 - 1.17)
Years on ART, median (IQR) 4 (2 - 7) 4 (2 - 7) 1.09 (1.08 - 1.11) 4 (2 - 7) 1.07 (1.06 - 1.08)
aOR = adjusted odds ratio; CI = confidence interval; ART = antiretroviral treatment; IQR = interquartile range.
